Tenaya Therapeutics Statistics
Share Statistics
Tenaya Therapeutics has 79.22M shares outstanding. The number of shares has increased by 15.82% in one year.
| Shares Outstanding | 79.22M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.47% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 65.64M |
| Failed to Deliver (FTD) Shares | 58 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 5.24M, so 6.62% of the outstanding shares have been sold short.
| Short Interest | 5.24M |
| Short % of Shares Out | 6.62% |
| Short % of Float | 8% |
| Short Ratio (days to cover) | 8.19 |
Valuation Ratios
The PE ratio is -1.93 and the forward PE ratio is -1.77.
| PE Ratio | -1.93 |
| Forward PE | -1.77 |
| PS Ratio | 0 |
| Forward PS | 47.3 |
| PB Ratio | 1.71 |
| P/FCF Ratio | -2.31 |
| PEG Ratio | n/a |
Enterprise Valuation
Tenaya Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 4.91, with a Debt / Equity ratio of 0.03.
| Current Ratio | 4.91 |
| Quick Ratio | 4.91 |
| Debt / Equity | 0.03 |
| Total Debt / Capitalization | 3 |
| Cash Flow / Debt | -23.63 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.89% and return on capital (ROIC) is -86.4%.
| Return on Equity (ROE) | -0.89% |
| Return on Assets (ROA) | -0.73% |
| Return on Capital (ROIC) | -86.4% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -886.31K |
| Employee Count | 140 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 32.21% in the last 52 weeks. The beta is 2.35, so Tenaya Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.35 |
| 52-Week Price Change | 32.21% |
| 50-Day Moving Average | 2.4 |
| 200-Day Moving Average | 3.38 |
| Relative Strength Index (RSI) | 46.73 |
| Average Volume (20 Days) | 3.14M |
Income Statement
In the last 12 months, Tenaya Therapeutics had revenue of $0 and earned -$124.08M in profits. Earnings per share was $-1.68.
| Revenue | 0 |
| Gross Profit | -8.69M |
| Operating Income | -131.19M |
| Net Income | -124.08M |
| EBITDA | -122.51M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.68 |
Balance Sheet
The company has $45.68M in cash and $12.42M in debt, giving a net cash position of $33.26M.
| Cash & Cash Equivalents | 45.68M |
| Total Debt | 12.42M |
| Net Cash | 33.26M |
| Retained Earnings | -403.28M |
| Total Assets | 140.58M |
| Working Capital | 69.15M |
Cash Flow
In the last 12 months, operating cash flow was -$102.07M and capital expenditures -$1.24M, giving a free cash flow of -$103.31M.
| Operating Cash Flow | -102.07M |
| Capital Expenditures | -1.24M |
| Free Cash Flow | -103.31M |
| FCF Per Share | -1.4 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
TNYA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -61.09% |
| FCF Yield | -47.44% |
Analyst Forecast
The average price target for TNYA is $18, which is 554.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $18 |
| Price Target Difference | 554.5% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -1.8 |
| Piotroski F-Score | 2 |